Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC
Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer
Adagrasib Improves Survival, Responses in KRASG12C-mutated Advanced NSCLC
DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC